A Phase 2a Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura.

Trial Profile

A Phase 2a Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs NXN 188 (Primary)
  • Indications Migraine with aura
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jun 2011 Results presented at the 15th Congress of the International Headache Society.
    • 28 Jul 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 24 Apr 2009 Planned end date ( Dec 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top